Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage
Hiroki Mizukami, … , Konrad Sandhoff, Richard L. Proia
Hiroki Mizukami, … , Konrad Sandhoff, Richard L. Proia
Published May 1, 2002
Citation Information: J Clin Invest. 2002;109(9):1215-1221. https://doi.org/10.1172/JCI14530.
View: Text | PDF
Categories: Article Genetics

Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage

  • Text
  • PDF
Abstract

Gaucher disease, the most common lysosomal storage disease, is caused by a deficiency of glucocerebrosidase resulting in the impairment of glucosylceramide degradation. The hallmark of the disease is the presence of the Gaucher cell, a macrophage containing much of the stored glucosylceramide found in tissues, which is believed to cause many of the clinical manifestations of the disease. We have developed adult mice carrying the Gaucher disease L444P point mutation in the glucocerebrosidase (Gba) gene and exhibiting a partial enzyme deficiency. The mutant mice demonstrate multisystem inflammation, including evidence of B cell hyperproliferation, an aspect of the disease found in some patients. However, the mutant mice do not accumulate large amounts of glucosylceramide or exhibit classic Gaucher cells in tissues.

Authors

Hiroki Mizukami, Yide Mi, Ryuichi Wada, Mari Kono, Tadashi Yamashita, Yujing Liu, Norbert Werth, Roger Sandhoff, Konrad Sandhoff, Richard L. Proia

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Degradation and synthesis of glucosylceramide, and derivation of GbaL444...
Degradation and synthesis of glucosylceramide, and derivation of GbaL444P/L444P mice. (a) Pathway of glucosylceramide degradation and synthesis. Glucosylceramide synthase is encoded by the Ugcg gene. Glucocerebrosidase (known also as acid β-glucosidase) is encoded by the Gba gene. (b) Breeding scheme to derive adult GbaL444P/L444 mice. As described in Methods, heterozygous mice with the L444P mutation in the Gba gene were cross-bred with mice carrying a disrupted Ugcg allele (UgcgKO) to eventually obtain adult mice with the genotype GbaL444P/L444PUgcg+/KO. These double mutant mice were intercrossed to obtain adult mice with the genotype GbaL444P/L444PUgcg+/+.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts